Findings showed the risk of disease progression or death was reduced by 79% with nivolumab and ipilimumab combination therapy vs chemotherapy (hazard ratio [HR], 0.21 [95% CI, 0.14-0.32]; P ...

41.7% with nivolumab/ipilimumab, and 23% with nivolumab). Similar differences existed for clinical to pathologic downstaging after neoadjuvant therapy (46.7%, 41.7%, and 23%). Patients who had a ...

The optimal duration of treatment with each drug has yet ... data from the phase II CheckMate 142 trial suggested nivolumab plus ipilimumab provided better outcomes than did single-agent nivolumab.

The EC has approved BMS Opdivo in combination with Yervoy as a first-line treatment for adults with unresectable or advanced HCC.

Dr. Emre Yekedüz discusses his top 3 key takeaways from attending the 2025 ASCO Genitourinary (GU) Cancers Symposium.

Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs) found that patients responded better to a combination of two ...

Our data clearly show that it is feasible and safe to implement stepwise acceleration of nivolumab and pembrolizumab administration to a 10-minute infusion time,” the researchers wrote.

Chronic cutaneous adverse events affected 8% of patients after checkpoint inhibitor therapy in a cohort study, often ...

During a live event, Thach-Giao Truong, MD, moderated a discussion on treating a 78-year-old patient with metastatic melanoma ...

The researchers called for further study to understand the mechanism of the relationship between obesity and ICI outcomes.